APPROVED FOR USE IN 3 INDICATIONS

THE BTK INHIBITOR DEMONSTRATED TO PROVIDE
COMPLETE AND SUSTAINED INHIBITION1,2

Waldenström’s Macroglobulinemia

WM

PREVIOUSLY TREATED
Mantle Cell Lymphoma

MCL

RELAPSED/REFRACTORY
Marginal Zone Lymphoma

MZL

24-hour inhibition of BTK was maintained at 100% in PBMCs and 94% to 100% in lymph nodes when taken at the recommended total daily dose of 320 mg. The clinical significance of 100% inhibition has not been established.1,2

BTK=Bruton’s tyrosine kinase; PBMCs=peripheral blood mononuclear cells. R/R=relapsed/refractory.

INDICATIONS

BRUKINSA® (zanubrutinib) is a kinase inhibitor indicated for the treatment of adult patients with:

  • • Waldenström’s macroglobulinemia (WM).
  • • Mantle cell lymphoma (MCL) who have received at least one prior therapy.
  • • Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.
The MCL and MZL indications are approved under accelerated approval based on overall response rate. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Hemorrhage

Fatal and serious hemorrhagic events have occurred in patients with hematological malignancies treated with BRUKINSA monotherapy. Grade 3 or higher hemorrhage events including intracranial and gastrointestinal hemorrhage, hematuria and hemothorax have been reported in 3.4% of patients treated with BRUKINSA monotherapy. Hemorrhage events of any grade occurred in 35% of patients treated with BRUKINSA monotherapy.

Bleeding events have occurred in patients with and without concomitant antiplatelet or anticoagulation therapy. Co-administration of BRUKINSA with antiplatelet or anticoagulant medications may further increase the risk of hemorrhage.

Monitor for signs and symptoms of bleeding. Discontinue BRUKINSA if intracranial hemorrhage of any grade occurs. Consider the benefit-risk of withholding BRUKINSA for 3-7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding.

APPROVED FOR USE IN 3 INDICATIONS
THE BTK INHIBITOR
DEMONSTRATED TO PROVIDE
COMPLETE AND
SUSTAINED INHIBITION
1,2

Waldenström’s Macroglobulinemia

WM

PREVIOUSLY TREATED
Mantle Cell Lymphoma

MCL

RELAPSED/REFRACTORY
Marginal Zone Lymphoma

MZL
The Brukinsa Difference
Efficacy
Safety
Dosing
Patient Support
WM
MCL
MZL
Marginal Zone Lymphoma (MZL)